YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Provided consolidated earnings guidance for the six months ended 30 June 2016. The board of directors of the company announced that, based on the currently available unaudited management accounts of the group and the preliminary assessment by the company's management, it is expected that the group will record an increase in profit attributable to equity shareholders of not less than 35% for the six months ended 30 June 2016, as compared to the six months ended 30 June 2015. The expected growth in profit attributable to equity shareholders is primarily attributed to: the significant increase in the sales volume of Kewei, one of the company's key products, in the first half of this year; and the continuous improvement of the professional academic marketing promotion abilities of the company.